Hodgkin's lymphoma (HL) is one of the most curable adult malignancies. However, management of disease refractory to primary induction or relapsing after remission becomes challenging and long-term disease control can only be achieved by salvage chemotherapy followed by autologous stem cell transplantation (ASCT). 1 On the other hand, relapse post ASCT is more challenging, and even though numerous salvage options are available, no standard recommendations for relapse post ASCT have been established. The salvage options include the following: novel immunotherapeutic agents such as anti CD30 Ab like Brentuximab Vedotin (Bv), 2 chemotherapy such as bendamustine (Benda), [3] [4] [5] combination of Bv and chemotherapy, anti-PD-1 Ab like Nivolumab, 6 and allogeneic hematopoietic stem cell transplantation (allo-SCT). 7 Several reports are available on safety and efficacy of Bv; 8, 9 however, data are scarce on the use of Nivolumab before or after transplantation. We report a retrospective multicenter study to assess the outcomes of HL patients treated with Nivolumab before or after allo-SCT.
This study was conducted in two transplant referral centers in Lebanon: the American University of Beirut Medical Centre and Makassed University Hospital. We identified and analyzed the outcome and toxicity in 11 patients with HL treated with Nivolumab before or after allo-SCT. Nine patients received Nivolumab as a bridge to allo-SCT, while two patients received it as salvage for relapse post allo-SCT. The primary end point of the study was the feasibility (safety) of Nivolumab before or after allo-SCT. Secondary end points included objective response rate (ORR), GVHD, successful bridging to allo-SCT when relevant and transplant outcomes. Chimerism fragment analysis was done via amplification of short tandem repeat sequences on DNA extracted from total peripheral blood white cells on days 30, 60, 90 and beyond. Complete donor chimerism is defined by more than 95% donor chimerism.
All patients had disease evaluation after the second and sixth cycle of Nivolumab with positron emission and computed tomography. The adverse events were collected from the charts and documented according to common terminology used in regular clinical practice, and stratified according to incidence, severity and type. In Lebanon, third party payers cover Nivolumab for HL patients refractory to multiple lines of chemotherapy, including Bv and Bendamustine. This drove both centers to adapt the same treatment strategy.
Nine patients received Nivolumab as a bridge to allo-SCT. The median age at diagnosis was 28 years (range, 20-38). Five patients had Stage III or higher disease at diagnosis. All patients received front-line ABVD. One patient was primary refractory; the others had relapsed disease and received salvage chemotherapy followed by ASCT. Five patients received radiotherapy post ASCT. All patients relapsed post ASCT with a median time to relapse of 7 months (range, 1-24 months). Seven patients (78%) failed Bv salvage post ASCT, prior to initiation of Nivolumab; the remaining two patients were refractory to Bv prior to ASCT, so they were immediately salvaged with Nivolumab. None of the patients received donor lymphocyte infusion (DLI) post transplant.
The median age at Nivolumab initiation was 29 years (range, 22-41). The median number of treatment lines prior to Nivolumab and between ASCT and Nivolumab were 5 (range, 4-7) and 1 (range, 0-2), respectively. The median follow-up from Nivolumab initiation and from allo-SCT was 16 (range, 10-26) and 10 (range, 5-19) months, respectively. All patient and disease characteristics are listed in Table 1 .
All patients received a median of eight cycles (range, 6-20) of Nivolumab. The treatment was well tolerated, with infrequent adverse events. None of them required Nivolumab discontinuation, interruption or dose reduction. However, one patient developed recurrent fever at every Nivolumab infusion, which was successfully managed with short courses of systemic corticosteroids and antipyretics. This is similar to the previously described cases of 'steroid-responsive febrile syndrome'. 10 None of the patients had to interrupt treatment because of disease progression. All patients proceeded with allo-SCT immediately after Nivolumab, using mobilized peripheral stem cells from a haplo-identical donor (haplo: six = 67%), or from a matched related donor (three = 33%). The median time between the last Nivolumab dose and allo-SCT was 44 days (range, 23-100). At allo-SCT, three patients were in CR, four in PR, and the remaining two patients progressed under Nivolumab treatment, and were transplanted with persistent disease (PD).
No patients experienced graft rejection and all patients had complete donor chimerism by day 100. The median number of days to reach an ANC of more than 500/mm 3 was 15 (10-19) days. The median number of days to reach a platelet count higher than 20 × 10 9 /L was 21 (0-33) days. Several patients had primary or secondary cytopenias; two patients are still RBC-and platelet-transfusion-dependent. All our patients presented a grade II to IV acute GVHD (details in Table 1 ), while three patients (33%) had also a chronic GVHD (two mild, one severe). Seven patients (78%) had CMV reactivation reactivation, at a median of 38 days (range, 30-47) post allo-SCT. Four patients (44%) had recovery of their CMV reactivation, while three are still under treatment at last follow-up. One patient was treated for EBV reactivation on day +27 post allo-SCT and recovered after 27 days. We did not observe any HHV6 infection. However, six (67%) patients had hemorrhagic cystitis (five patients were positive by PCR for BKV on urine and blood specimens, one patient was PCR-negative) after a median of 32 days (range, 23-41) and five patients recovered, while one still has refractory hemorrhagic cystitis at last follow-up. One patient had veno-occlusive disease on day +5 post allo-SCT treated with defibrotide 25 mg/kg/day and resolved. This patient developed prolonged liver disease characterized by elevated bilirubin (total bilirubin 28 mg/dL) and transaminases (AST 1400 IU/L per ALT 2000 IU/L), resistant to systemic steroids. Liver biopsy showed cholestasis and acute portal inflammation with no support for GVHD. Liver function continued to deteriorate, resulting in patient death at 6 months post transplant while he was in CR. One patient with ABO mismatch had thrombotic microangiopathic hemolytic anemia treated with Eculuzumab, Rituximab, bortezomib, plasma Letter to the Editor exchange and growth factors and made partial RBC and full platelet recovery. At last follow-up, eight patients are alive, seven (78%) in CR and one in stable disease. Interestingly, none of our patients progressed post allo-SCT. However, 3 patients are still suffering from comorbidities (1 with incomplete RBC recovery with hemolytic anemia; 1 with hemorrhagic cystitis, recurrent CMV infection and pneumonia; 1 with recurrent CMV and pneumonia).
Two patients were treated with Nivolumab for disease relapse post allo-SCT. None of them received Nivolumab before allo-SCT.
A 35-year-old man with chronic hepatitis B diagnosed with HL refractory to ABVD salvaged with ICE and underwent ASCT in CR. However, patient relapsed 3 months after ASCT, failed salvage Bv and achieved his third CR after shifting to Gemzar-Navelbine and underwent allo-SCT from a matched related donor. Post allo-SCT, the patient did not experience any GVHD or post-transplant complications. However, his disease relapsed 3 months post allo-SCT. He was salvaged with escalated DLI, Gemzar-Navelbine and achieved his fourth CR. After 1 month, his disease relapsed again and was successfully salvaged with Benda and he achieved his fifth CR, then he was consolidated with a second transplant from a haplo-identical donor. He did not experience any significant transplant complication except BKV reactivation and hemorrhagic cystitis. His lymphoma remained in remission for 10 months after his second allo-SCT, and he did not receive DLI. The patient had localized relapse in the soft tissues of the left shoulder and he was started on Nivolumab 3 mg/kg; however, and after 10 days from the first cycle, he developed a severe grade III steroid-resistant ocular, liver and skin GVHD. This GVHD was documented on the skin and liver biopsy. The patient was treated with steroids and Ruxolitinib. Nivolumab was discontinued, but he achieved impressive clinical CR documented on magnetic resonance imaging. Unfortunately, despite antifungal prophylaxis, he developed severe fungal infection (mucormycosis) and passed away 13 weeks after Nivolumab salvage.
A 33-year-old man diagnosed with HL, relapsed after ABVD, salvaged with ICE and underwent ASCT in CR2. Patient relapsed 31 months post ASCT, successfully salvaged with Bv, and underwent allo-SCT from a matched related donor in PR. No GVHD or post-transplant complications were observed. The patient achieved CR post allo-SCT and maintained this status for 9 months post transplant. At relapse, he received salvage therapy with 10 cycles of Bv and three doses of escalated DLI. He achieved only PR and was shifted to Nivolumab 3 mg/kg (one dose) 15 weeks after the last dose of DLI (28 months post allo-SCT). However, after 3 weeks, the patient developed severe acute Grade III GVHD involving skin, GI and liver, confirmed by biopsy. Skin and GI GVHD were steroid-responsive, but his liver GVHD was steroid refractory. This liver GVHD responded to Ruxolitinib (10 mgx2/ day), cyclosporine and nine sessions of extracorporeal photopheresis. At last follow-up, 8 months after Nivolumab, the patient is still alive and in CR from HL and from GVHD, maintained on Ruxolitinib and cyclosporine.
The anti-PD-1 monoclonal Abs Nivolumab showed promising activity in subjects with refractory HL including Bv-resistant HL. 8, 10, 11 In these patients, allo-SCT represents the only potentially curative option. However, interactions of PD-1 Abs with the transplant procedure have not been investigated. The most recent clinical trial investigating the use of anti-PD-1 Abs excluded patients undergoing allo-SCT. 8, 10, 11 To the best of our knowledge, this is the largest series investigating the outcomes of patients receiving PD-1-blocking agents in relapsed refractory HL before or after allo-SCT.
Recently published phase-I open-label dose-escalation trial of Nivolumab for patients with hematological malignancies reported an ORR ranging from 15 to 40% depending on the lymphomas and myeloma subtype; however, none of the patients included had HL. Another ongoing phase 1 study using escalated-dose Nivolumab (1-3 mg/kg) on 23 patients with relapsed or refractory HL reported an ORR of 87% with 17% in CR and 70% in PR. 6 In our study, at last follow-up, we have a higher ORR with seven patients in CR (78%) and one SD (11%) when assessed after the treatment sequence Nivolumab transplant. This higher response rate may be attributed to the combined immunological effects of Nivolumab and allo-SCT as well as the difference in doses; while other studies used an escalated dose of 1-3 mg/kg, we used a standard dose of 3 mg/kg on all our patients. The same phase one open-label dose-escalation trial investigated the safety and efficacy of Nivolumab; however, it excluded all patients with a history of allo-SCT. 6 Even though six of their patients proceeded with an allo-SCT post Nivolumab, they did not report on post-transplant complications. A recently published retrospective study reports on 39 patients with lymphomas who received PD-1 inhibitors Nivolumab or Pembrolizumab prior to allo-SCT. They report a 1-year cumulative incidence of grade II-IV aGVHD of 44%, and chronic GVHD of 41%. Interestingly, none of their patients who received bone marrow as stem cell source developed grade II-IV aGVHD, while 32% of patients with PBSC grafts developed aGVHD. Comparing these results to ours, we have a higher incidence of aGVHD. This may be attributed to the difference in stem cell source while we used PBSC for all of our patients; they used bone marrow and PBSC. They also report a lower ORR then ours, maybe because of different types of diseases (all of our cases were HL, while they had a more heterogeneous sample with different lymphomas), and finally the difference in the choice of PD-1 inhibitor. 12 The effect of pre-transplant Nivolumab on stem cell engraftment has not been reported in the literature. The use of PD-1-blocking agents in the allo-SCT setting has raised several issues including the issue of whether it increases GVHD incidence and severity. Our study included nine patients who received Nivolumab as most recent therapy prior to allo-SCT with a median of 44 days (range, 23-100) between the last Nivolumab and allo-SCT. After a median follow-up of 10 months (5-19) post allo-SCT, remarkably, all nine patients experienced acute GVHD, with five patients (56%) grade III and one patient grade IV. Three patients (25%) had chronic GVHD (two mild, one severe; Table 1) Considering the residual half-life of Nivolumab is 26.7 days, it is likely that residual circulating Ab was present in most patients. 13 It also should be noted that all patients received stem cell infusions with low CD3+ cell count (median 2.5 × 10 6 /kg) and eight patients (89%) received ATG, making them less likely to develop acute GVHD.
A recently published phase 1/1b multicenter dose-escalation study investigated the safety and efficacy of a different PD-1 inhibitor (ipilimumab) in 28 patients with different hematological malignancies including acute leukemia relapsing post allo-SCT. They report lower rates of response to therapy and lower incidence of GVHD (14%). While they used an escalated dose, we have used a fixed dose of Nivolumab. 14 Villasboas et al. 15 recently published two heavily pretreated HL cases who received Pembrolizumab salvage for relapse post allo-SCT. Both patients responded (one PR and one CR). However, none of the two patients developed GVHD post PD-1 inhibitor. Our study also included two patients who received Nivolumab as salvage post allo-SCT. While both of our cases had allo-SCT from a haplo-identical donor, their cases were from a matched related donor. In addition, they infused steroids with Pembrolizumab and a longer interval of time to initiation of the PD-1 inhibitor in their cases. Our first patient started on Nivolumab 9 months post allo-SCT and developed after the first dose grade III steroidresistant GVHD that necessitated Nivolumab discontinuation. Interestingly, the second patient was started on Nivolumab 28 months post allo-SCT but 15 weeks after DLI. After a single dose of Nivolumab, he developed Grade III acute GVHD. These observations suggest that Nivolumab may increase the incidence of acute GVHD when used as a bridge to allo-SCT or salvage post allo-SCT. It should also be emphasized that the use of Nivolumab post allo-SCT may lead to life-threatening acute GVHD, with other significant post-transplant morbidity including veno-occlusive disease, thrombotic microangiopathic, CMV reactivation, hemorrhagic cystitis and other infectious or inflammatory complications. However, it should be noted that patients were heavily pretreated receiving a median of six lines of therapy prior to transplant; two received sequential conditioning for persistent disease at transplant. Although we cannot attribute all these toxicities to Nivolumab, however, it should be used cautiously in heavily pretreated patients.
Although a limitation of our study is the small sample size, in this observational retrospective study our data suggest that Nivolumab can be an effective bridge to allo-SCT in patients with relapsed and refractory HL, including in haplo setting. Even though it does not affect stem cell engraftment, it may contribute to an increased incidence of acute GVHD and post-transplant morbidity when used pre-or post allo-SCT.
